Hydroxychloroquine Dosing and Monitoring in Sjögren Syndrome

Dosing Recommendations

The European League Against Rheumatism (EULAR) suggests that hydroxychloroquine may be considered for patients with Sjögren's syndrome who have mild systemic manifestations, although the evidence for clinical efficacy is weak 5
For patients with mild systemic manifestations, hydroxychloroquine 200-400 mg/day may be considered, recognizing that the evidence for clinical efficacy is weak 5
Hydroxychloroquine is not indicated as primary treatment for isolated sicca symptoms without systemic disease 5

In patients with Sjögren's syndrome secondary to systemic lupus erythematosus, hydroxychloroquine is strongly indicated due to its proven benefits 6
Hydroxychloroquine reduces lupus flares 2.5 times, including renal flares, and decreases renal damage progression 6
Hydroxychloroquine reduces cardiovascular events, thrombotic events, improves lipid profile, and decreases mortality 6
Hydroxychloroquine allows for reduction of corticosteroid doses and is safe during pregnancy 6

Do not exceed 5 mg/kg of actual body weight per day to minimize the risk of retinal toxicity 6, 7
In patients with glomerular filtration <30 ml/min/1.73 m², reduce the dose by 25% 6
Initiate annual ophthalmologic monitoring after 5 years of treatment in patients without additional risk factors 6, 7
Use spectral-domain optical coherence tomography and automated visual fields (10-2 protocol) as primary tests 7
The risk of retinopathy is <1% up to 5 years, <2% up to 10 years, but can reach >20% after 20 years 6, 7

Hydroxychloroquine can cause significant adverse effects, including skin hyperpigmentation, muscle weakness, and visual changes 6
Rarely, hydroxychloroquine can cause cardiotoxicity with high cumulative exposure 6
Do not discontinue hydroxychloroquine until retinopathy is definitive, especially in patients with active disease - questionable findings should be verified before discontinuing 7
Co-management with rheumatology is essential due to possible systemic comorbidities, risk of vasculitis, and lymphoproliferative disorders 8, 9